This site is for US healthcare professionals to provide online access to current, accurate, scientific information about our products. It is prepared by Janssen Medical Information and is not intended for promotional purposes, nor for medical advice.

  1. Home
  2. Announcements
  3. Selected Announcement

Data presented at American Diabetes Association (ADA) 2020

Please refer to the ADA website directly for oral presentations and posters available for registered attendees at: https://professional.diabetes.org/scientific-sessions or contact us by visiting askjanssenmedinfo.com or by calling 1-800-JANSSEN (1-800-526-7736).

Abstracts:
Ferrannini E, Baldi S, Scozzaro T, et al. The redox balance predicts both cardiovascular (CV) and renal outcomes in CANVAS.
Abstract URL: https://diabetes.diabetesjournals.org/content/69/Supplement_1/139-LB

Li J, Sen T, Neal B, et al. Association between the inflammatory marker GDF-15 and kidney disease progression: results from the CANVAS Trial. 
Abstract URL: https://diabetes.diabetesjournals.org/content/69/Supplement_1/1120-P

Li J, Neal B, Heerspink HL, et al. Mediators of the effects of canagliflozin (CANA) on heart failure (HF) and CV death in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). 
Abstract URL: https://diabetes.diabetesjournals.org/content/69/Supplement_1/1130-P

Li J, Jardine MJ, Neal B, et al. Effect of canagliflozin on total hospitalization for heart failure events in patients with type 2 diabetes and chronic kidney disease. 
Abstract URL: https://diabetes.diabetesjournals.org/content/69/Supplement_1/27-OR

Oshima M, Jardine MJ, Agarwal R, et al. Acute declines in EGFR during treatment with canagliflozin and its implications for clinical practice: insights from CREDENCE. 
Abstract URL: https://diabetes.diabetesjournals.org/content/69/Supplement_1/26-OR

Peters K, Xu J, Bringans S, et al. Validation of the PromarkerD Test for predicting renal decline in type 2 diabetes in the Canagliflozin Cardiovascular Assessment Study (CANVAS). 
Abstract URL: https://diabetes.diabetesjournals.org/content/69/Supplement_1/1118-P

Pilon D, Durkin M, Manceur A, Ghelerter I, Lafeuille M, Lefebvre P. Comparison of hospitalization for heart failure (HHF) among patients with type 2 diabetes mellitus (T2DM) and macroalbuminuria initiated on canagliflozin (CANA) or a DPP-4. 
Abstract URL: https://diabetes.diabetesjournals.org/content/69/Supplement_1/1142-P

Sattar N, Xu J, Butler J, et al. Stress cardiac biomarkers and adverse cardiac outcomes in the CANagliflozin CardioVascular Assessment Study (CANVAS). 
Abstract URL: https://diabetes.diabetesjournals.org/content/69/Supplement_1/1123-P

Sen T, Li J, Neal B, et al. Biomarkers of tubular injury and effects of canagliflozin in the CANVAS Trial. 
Abstract URL: https://diabetes.diabetesjournals.org/content/69/Supplement_1/1098-P